Special regulatory designations will act as a major boost for the global metabolic disorders therapeutics market. These special designations help vendors launch their drugs quickly into the market. Also, in a few cases, governments offer tax incentives for such drugs. The US Food and Drug Administration (FDA) gave the orphan drug designation for a few already approved drugs such as Elelyso,

Zavesca, and Cerezyme. Regulatory bodies, at times, give these designations to pipeline products. For instance, Amicus Therapeutics' migalastat is under regulatory review in the US. However, the drug received orphan designation from the FDA for Fabry disease in June 2016.Oral insulin products are under investigation and, once approved, will emerge as new generation drugs for diabetes management. Generex Biotechnology Corporation’s Oral-lyn, Oramed Pharmaceutical's ORMD-0801 and ORMD-0901,and Biocon’s IN-105 are the upcoming oral drugs for the treatment of diabetes.

PART 01: Executive summary 8

Highlights 8

PART 02: Scope of the report 9

Market overview 9

Top-vendor offerings 11

PART 03: Market research methodology 14

Research methodology 14

Economic indicators 14

PART 04: Introduction 15

Key market highlights 15

PART 05: Pipeline portfolio 18

Pipeline portfolio: Global diabetes drugs market 18

Pipeline portfolio: Global hyperphosphatemia drugs

market 30

Pipeline portfolio: Global anti-obesity drugs market 32

PART 06: Market landscape 35

Market overview 35

Market size and forecast 36

Five forces analysis 40

PART 07: Market segmentation by type of disease 41

Diabetes 41

Obesity 42

Hypercholesterolemia 42

Lysosomal storage diseases 42

PART 08: Global diabetes drugs market 45

Market overview 45

Global type 1 diabetes market 46

Global type 2 diabetes drugs market 48

Vendors in global diabetes drugs market 50

PART 09: Global hypercholesterolemia drugs market 52

Market overview 52

Vendors in global hypercholesterolemia drugs market 55

PART 10: Global lysosomal storage diseases market 57

Market overview 57

Vendors in global lysosomal storage disorders drugs

market 61

PART 11: Global anti-obesity drugs market 62

Market overview 62

Vendors in global anti-obesity drugs market 64

PART 12: Geographical segmentation 66

Global metabolic disorders therapeutics market by

geography 2015-2020 66

Metabolic disorders therapeutics market in Americas 70

Metabolic disorders therapeutics market in EMEA 72

Metabolic disorders therapeutics market in APAC 75

PART 13: Market drivers 77

Patient assistance programs 77

Special regulatory designations for rare diseases 78

Increase in academia-industry collaborations for drug

development 79

PART 14: Impact of drivers 80

PART 15: Market challenges 81

Low compliance and adherence rates 81

High cost of therapies 82

Complex storage conditions and distribution policies for

insulin 83

PART 16: Impact of drivers and challenges 84

PART 17: Market trends 85

Focus on oral insulin therapies 85

Strong and diversified pipeline portfolio 86

Strategic collaborations and acquisitions 88

PART 18: Vendor landscape 90

Competitive scenario 90

Other prominent vendors 97

PART 19: Key vendor analysis 113

Novo Nordisk 113

Sanofi 124

Merck 135

AstraZeneca 142

Eli Lilly 150

PART 20: Appendix 159

List of abbreviations 159

PART 21: Explore Technavio 161